BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 27875414)

  • 1. The Influence of Histologic Subtype in Predicting Survival of Lung Cancer Patients With Spinal Metastases.
    Kumar N; Tan KA; Tan JH; Zaw AS; Hey HWD; Ruiz J; Stone E
    Clin Spine Surg; 2018 Feb; 31(1):E1-E7. PubMed ID: 27875414
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Survival and prognostic factors in patients with stable and unstable spinal bone metastases from solid tumors: a retrospective analysis of 915 cases.
    Wolf RJ; Foerster R; Bruckner T; Bostel T; Schlampp I; Debus J; Rief H;
    BMC Cancer; 2016 Jul; 16():528. PubMed ID: 27456003
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic factors and outcome of surgically treated patients with brain metastases of non-small cell lung cancer.
    She C; Wang R; Lu C; Sun Z; Li P; Yin Q; Liu Q; Wang P; Li W
    Thorac Cancer; 2019 Feb; 10(2):137-142. PubMed ID: 30485664
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Preoperative palsy score has no significant association with survival in non-small-cell lung cancer patients with spinal metastases who undergo spinal surgery.
    Chen YJ; Chen HT; Hsu HC
    J Orthop Surg Res; 2015 Sep; 10():149. PubMed ID: 26381378
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of Scoring Systems and Prognostic Factors in Patients With Spinal Metastases From Lung Cancer.
    Tan JH; Tan KA; Zaw AS; Thomas AC; Hey HW; Soo RA; Kumar N
    Spine (Phila Pa 1976); 2016 Apr; 41(7):638-44. PubMed ID: 27018903
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Surgical results of metastatic spinal cord compression (MSCC) from non-small cell lung cancer (NSCLC): analysis of functional outcome, survival time, and complication.
    Park SJ; Lee CS; Chung SS
    Spine J; 2016 Mar; 16(3):322-8. PubMed ID: 26586194
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Overall survival and prognostic factors in patients with spinal metastases from lung cancer treated with and without epidermal growth factor receptor tyrosine kinase inhibitors.
    Dohzono S; Sasaoka R; Takamatsu K; Nakamura H
    Int J Clin Oncol; 2017 Aug; 22(4):698-705. PubMed ID: 28361340
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic factors for patients with spinal metastases from lung cancer.
    Ogihara S; Seichi A; Hozumi T; Oka H; Ieki R; Nakamura K; Kondoh T
    Spine (Phila Pa 1976); 2006 Jun; 31(14):1585-90. PubMed ID: 16778693
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognostic Factors and Comparison of Conservative Treatment, Percutaneous Vertebroplasty, and Open Surgery in the Treatment of Spinal Metastases from Lung Cancer.
    Yang SZ; Tang Y; Zhang Y; Chen WG; Sun J; Chu TW
    World Neurosurg; 2017 Dec; 108():163-175. PubMed ID: 28867314
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic indices in stereotactic radiotherapy of brain metastases of non-small cell lung cancer.
    Kaul D; Angelidis A; Budach V; Ghadjar P; Kufeld M; Badakhshi H
    Radiat Oncol; 2015 Nov; 10():244. PubMed ID: 26611493
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Non-small cell lung cancer patients with brain metastases treated with first-line platinum-doublet chemotherapy: Analysis from the European FRAME study.
    Moro-Sibilot D; Smit E; de Castro Carpeño J; Lesniewski-Kmak K; Aerts JG; Villatoro R; Kraaij K; Nacerddine K; Dyachkova Y; Smith KT; Girvan A; Visseren-Grul C; Schnabel PA
    Lung Cancer; 2015 Dec; 90(3):427-32. PubMed ID: 26791802
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Spine-specific skeletal related events and mortality in non-small cell lung cancer patients: a single-institution analysis.
    Adogwa O; Rubio DR; Buchowski JM; D'Souza A; Shlykov MA; Jennings JW
    J Neurosurg Spine; 2022 Jan; 36(1):125-132. PubMed ID: 33254136
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prediction of survival prognosis after surgery in patients with symptomatic metastatic spinal cord compression from non-small cell lung cancer.
    Lei M; Liu Y; Tang C; Yang S; Liu S; Zhou S
    BMC Cancer; 2015 Nov; 15():853. PubMed ID: 26541141
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Leptomeningeal carcinomatosis in non-small-cell lung cancer patients: impact on survival and correlated prognostic factors.
    Lee SJ; Lee JI; Nam DH; Ahn YC; Han JH; Sun JM; Ahn JS; Park K; Ahn MJ
    J Thorac Oncol; 2013 Feb; 8(2):185-91. PubMed ID: 23328548
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Spinal metastases from lung cancer: Survival depends only on genotype, neurological and personal status, scarcely of surgical resection.
    Amelot A; Terrier LM; Cristini J; Buffenoir K; Pascal-Moussellard H; Carpentier A; Bonaccorsi R; Le Nail LR; Mathon B
    Surg Oncol; 2020 Sep; 34():51-56. PubMed ID: 32891353
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic factors and long-term survival in surgically treated brain metastases from non-small cell lung cancer.
    Enders F; Geisenberger C; Jungk C; Bermejo JL; Warta R; von Deimling A; Herold-Mende C; Unterberg A
    Clin Neurol Neurosurg; 2016 Mar; 142():72-80. PubMed ID: 26816105
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Radical treatment of synchronous oligometastatic non-small cell lung carcinoma (NSCLC): patient outcomes and prognostic factors.
    Griffioen GH; Toguri D; Dahele M; Warner A; de Haan PF; Rodrigues GB; Slotman BJ; Yaremko BP; Senan S; Palma DA
    Lung Cancer; 2013 Oct; 82(1):95-102. PubMed ID: 23973202
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Heterogeneity in Treatment Response of Spine Metastases to Spine Stereotactic Radiosurgery Within "Radiosensitive" Subtypes.
    Bernard V; Bishop AJ; Allen PK; Amini B; Wang XA; Li J; Tatsui CE; Rhines LD; Brown PD; Ghia AJ
    Int J Radiat Oncol Biol Phys; 2017 Dec; 99(5):1207-1215. PubMed ID: 29029886
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Docetaxel plus nintedanib versus docetaxel plus placebo in patients with previously treated non-small-cell lung cancer (LUME-Lung 1): a phase 3, double-blind, randomised controlled trial.
    Reck M; Kaiser R; Mellemgaard A; Douillard JY; Orlov S; Krzakowski M; von Pawel J; Gottfried M; Bondarenko I; Liao M; Gann CN; Barrueco J; Gaschler-Markefski B; Novello S;
    Lancet Oncol; 2014 Feb; 15(2):143-55. PubMed ID: 24411639
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Survival outcome according to KRAS mutation status in newly diagnosed patients with stage IV non-small cell lung cancer treated with platinum doublet chemotherapy.
    Brady AK; McNeill JD; Judy B; Bauml J; Evans TL; Cohen RB; Langer C; Vachani A; Aggarwal C
    Oncotarget; 2015 Oct; 6(30):30287-94. PubMed ID: 26471290
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.